| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| |
For the six Months Ended
April 30,
|
| |
| |
2020
|
|
2019
|
|
Net loss:
|
|
|
|
|
|
|
CAR-T Therapeutics
|
$
|
(1,125,363)
|
|
$
|
(3,517,219)
|
|
Cancer Vaccines
|
|
(365,867)
|
|
|
-
|
|
Anti-Viral Therapeutics
|
|
(309,504)
|
|
|
-
|
|
Cancer Diagnostics
|
|
(3,469,673)
|
|
|
(3,052,355)
|
|
Patent Licensing
|
|
(4,158)
|
|
|
(971,969)
|
|
Total
|
$
|
(5,274,565)
|
|
$
|
(7,541,543)
|
| |
|
|
|
|
|
|
Total operating costs and expenses
|
$
|
5,300,006
|
|
$
|
7,826,962
|
|
Less non-cash share-based compensation
|
|
(2,131,420)
|
|
|
(4,071,614)
|
|
Operating costs and expenses excluding
non-cash share-based compensation
|
$
|
3,168,586
|
|
$
|
3,755,348
|
| |
|
|
|
|
|
|
Operating costs and expenses excluding non-cash
share based compensation expense:
|
|
|
|
|
|
|
CAR-T Therapeutics
|
$
|
570,163
|
|
$
|
1,245,681
|
|
Cancer Vaccines
|
|
165,329
|
|
|
-
|
|
Anti-Viral Therapeutics
|
|
221,018
|
|
|
-
|
|
Cancer Diagnostics
|
|
2,208,813
|
|
|
1,417,967
|
|
Patent Licensing
|
|
3,263
|
|
|
1,091,700
|
|
Total
|
$
|
3,168,586
|
|
$
|
3,755,348
|
| |
For the Three Months Ended
April 30,
|
| |
| |
2020
|
|
2019
|
|
Net loss:
|
|
|
|
|
|
|
CAR-T Therapeutics
|
$
|
(495,030)
|
|
$
|
(1,029,934)
|
|
Cancer Vaccines
|
|
(170,271)
|
|
|
-
|
|
Anti-Viral Therapeutics
|
|
(309,504)
|
|
|
-
|
|
Cancer Diagnostics
|
|
(1,679,027)
|
|
|
(1,249,001)
|
|
Patent Licensing
|
|
(4,158)
|
|
|
(296,999)
|
|
Total
|
$
|
(2,657,990)
|
|
$
|
(2,574,934)
|
| |
|
|
|
|
|
|
Total operating costs and expenses
|
$
|
2,670,137
|
|
$
|
2,843,234
|
|
Less non-cash share-based compensation
|
|
(1,110,086)
|
|
|
(1,321,450)
|
|
Operating costs and expenses excluding
non-cash share-based compensation
|
$
|
1,560,051
|
|
$
|
1,521,784
|
| |
|
|
|
|
|
|
Operating costs and expenses excluding non-cash
share based compensation expense:
|
|
|
|
|
|
|
CAR-T Therapeutics
|
$
|
223,822
|
|
$
|
444,890
|
|
Cancer Vaccines
|
|
67,059
|
|
|
-
|
|
Anti-Viral Therapeutics
|
|
221,018
|
|
|
-
|
|
Cancer Diagnostics
|
|
1,044,889
|
|
|
658,433
|
|
Patent Licensing
|
|
3,263
|
|
|
418,461
|
|
Total
|
$
|
1,560,051
|
|
$
|
1,521,784
|
|
|
April 30,
2020
|
|
October 31,
2019
|
| |
|
|
Total assets:
|
|
|
|
|
|
|
CAR-T Therapeutics
|
$
|
1,011,316
|
|
$
|
2,382,460
|
|
Cancer Vaccines
|
|
287,831
|
|
|
489,881
|
|
Anti-Viral Therapeutics
|
|
384,326
|
|
|
-
|
|
Cancer Diagnostics
|
|
4,089,496
|
|
|
2,921,784
|
|
Patent Licensing
|
|
151,926
|
|
|
499,568
|
|
Total
|
$
|
5,924,895
|
|
$
|
6,293,693
|
|